Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-15
2005-03-15
Minnifield, N. M. (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S800000, C514S002600, C424S184100, C424S193100, C424S198100, C930S110000, C530S313000, C530S300000
Reexamination Certificate
active
06867191
ABSTRACT:
A lyophilizate, method of preparation, and use of the lyophilizate for gonad protection is described. The lyophilizate comprises cetrorelix dissolved in 30% (v/v) acetic acid, transferred to water, and freeze-dried.
REFERENCES:
patent: 3816386 (1974-06-01), Hedlund et al.
patent: 4372884 (1983-02-01), Brown et al.
patent: 4512923 (1985-04-01), Flegel et al.
patent: 4565804 (1986-01-01), Rivier et al.
patent: 4693993 (1987-09-01), Stewart et al.
patent: 4701499 (1987-10-01), Kornreich et al.
patent: 4711877 (1987-12-01), Moore
patent: 4716242 (1987-12-01), Engel et al.
patent: 4800191 (1989-01-01), Schally et al.
patent: 4908475 (1990-03-01), Callahan et al.
patent: 5198533 (1993-03-01), Schally et al.
patent: 5204335 (1993-04-01), Sauerbier et al.
patent: 5268360 (1993-12-01), Yoshikawa et al.
patent: 5446033 (1995-08-01), Engel et al.
patent: 5663145 (1997-09-01), Engel et al.
patent: 5728738 (1998-03-01), Engel et al.
patent: 5750131 (1998-05-01), Wichert et al.
patent: 5773032 (1998-06-01), Engel et al.
patent: 5945128 (1999-08-01), Deghenghi
patent: 5968895 (1999-10-01), Gefter et al.
patent: 6022860 (2000-02-01), Engel et al.
patent: 6054432 (2000-04-01), Engel et al.
patent: 6054555 (2000-04-01), Engel et al.
patent: 6071882 (2000-06-01), Engel et al.
patent: 6106805 (2000-08-01), Engel et al.
patent: 6214798 (2001-04-01), Semple et al.
patent: 6300313 (2001-10-01), Engel et al.
patent: 6680058 (2004-01-01), Enright et al.
patent: 6716817 (2004-04-01), Engel et al.
patent: 20020058035 (2002-05-01), Garnick et al.
patent: 20020099018 (2002-07-01), Engel et al.
patent: 20020103177 (2002-08-01), Cook et al.
patent: 20020147198 (2002-10-01), Chen et al.
patent: 20020198186 (2002-12-01), Engel et al.
patent: 20030092689 (2003-05-01), Escandon et al.
patent: 20030100509 (2003-05-01), Sarlikiotis et al.
patent: 20040072824 (2004-04-01), Telerman et al.
patent: 141 996 (1980-06-01), None
patent: 0 175 506 (1986-03-01), None
patent: 0 268 066 (1988-05-01), None
patent: 0 277 829 (1988-08-01), None
patent: 05-000963 (1991-10-01), None
patent: 61-87695 (1986-05-01), None
patent: 63-201199 (1988-08-01), None
patent: 0 299 402 (1989-01-01), None
patent: 64-034997 (1999-06-01), None
patent: WO 9113092 (1991-09-01), None
patent: WO 9116038 (1991-10-01), None
patent: WO 9119743 (1991-12-01), None
Shuttlesworth et al, Endocrinology, 2000, 141:37-49.*
Meistrich et al, J. Androl., Sep.-Oct. 2001, 22/5:809-817 Abstract Only.*
Shetty et al, Endocriinology, 2002, 143:3385-3396.*
Shetty et al, Endocrinology, 2000, 141:1735-1745.*
Redding et al, Cancer Research, 52/9:2538-2544, 1992.*
Gonzalez-Barcena et al, Urology, 45/2:275-281, 1995.*
Jungwirth et al, European J. Cancer 33/7:1141-1148, 1997.*
Klingmüller et al, Acta Endocrinologica 128:15-18, 1993.*
Behre et al, J. Clinical Endocrinology & Metabolism 75/2:393-398, 1992.*
Korkut et al, PNAS, USA; 88/3: 844-848, 1991.*
Gonzalez-Barcena et al Prostate, 24/2: 84-92, 1994.*
Budman et al, Anti Cancer Drugs 13/10:1011-1016, 2002.*
Horvath et al, PNAS, USA; 99/23:15048-53, 2002.*
Huirne et al, The Lancet, 358/9295:1793-1803, 2001.*
Bokser et al, Neuroendocrinology 54:136-145, 1991.*
Schally et al, Biomed. & Pharmacother. 46:465-471, 1992.*
Szepeshazi et al, The Prostate 18:255-270, 1991.*
Redding et al, Cancer Research, 52: 2538-2544, 1992.*
Srkabvic et al, Endocrinology 127/6: 3052-3060, 1990.*
Gonzalez-Barcena et al, The Prostate 24:84-92, 1994.*
Pinski et al, J. of Andrology 14/3: 164-169, 1993.*
Amory et al, Molecular and Cellular Endocrinology 182: 175-179, 2001.*
Comaru-Schally et al, J. Clinical Endocrinology and Metabolism, 83/11: 3826-3831, 1998.*
Schally et al, Peptides 20:1247-1262, 1999.*
Szende et al, PNAS, USA, 87:901-903, 1990.*
Jungwirth et al, The Prostate, 32:164-172, 1997.*
Emons et al, Human Reproduction Update 9/7:1364-1379, 1994.*
Meijer et al, J. of Urology 165/5, Suppl: 380 Abstract #1558, 2001.*
Lamharzi et al, Regulatory Peptides 77:185-192, 1998.*
Schally et al, Advanced Drug Delivery Reviews 28:157-169, 1997.*
Tunn et al, J. of Urology 157/4 Suppl: 141 Abstract #551, 1997.*
Tieva et al, BJU International, 91/3: 227-233, 2003.*
Behre et al, Human Reproduction 16/12: 2570-2577, 2001.*
Roth et al, Exp. Clin. Endocrinol. Diabetes 108:358-363, 2000.*
Roth et al, Expert Opin. Investig. Drugs. 11/9:1253-1259, 2002.*
Blithe et al, Trends in Endocrinology & Metabolism 12/6:238-240, 2001.*
Felberbaum et al, Infertility & Reproductive Medicine Clinics of N. America 12/1: 45-57, 2001.*
Schally et al, The Prostate 45: 158-166, 2000.*
Pinski et al, The Prostate 20: 213-224, 1992.*
Lamharzi et al, International J. Oncology 13: 429-435, 1998.*
Albano et al., “The Luteal Phase of Nonsupplemented Cycles After Ovarian Superovulation With Human Menopausal Gonadotropin and the Gonadotropin-Releasing Hormone Antagonist Cetrorelix,”Fertility and Sterility, vol. 70, No. 2, Aug. 1998, pp. 357-359.
Albano et al., “Ovarian Stimulation With HMG: Results of a Prospective Randomized Phase III European Study Comparing the Luteinizing Hormone-Releasing Hormone (LHRH)-Antagonist Cetrorelix and the LHRH-Agonist Buserelin,”Human Reproduction, vol. 15, No. 3, 2000, pp. 526-531.
Albano et al., “Hormonal Profile During the Follicular Phase in Cycles Stimulated with a Combination of Human Menopausal Gonadotrophin and Gonadotrophin-Releasing Hormone Antagonist (Cetrorelix),”Human Reproduction, vol. 11, No. 10, 1996, pp. 2114-2118.
Christin-Maitre et al., “Effect of Gonadotrophin-Releasing Hormone (GnRH) Antagonist During the LH Surge in Normal Women and During Controlled Ovarian Hyperstimulation,” Clinical Endocrinology, vol. 52, 2000, pp. 721-726.
Diedrich et al., Suppression of the Endogenous Luteinizing Hormone Surge by the Gonadotrophin-Releasing Hormone Antagonist Cetrorelix During Ovarian Stimulation,Human Reproduction, vol. 9, No. 5, 1994, pp. 788-791.
Felberbaum et al., “Ovarian Stimulation for In-Virtro Fertilization/Intracytoplasmic Sperm Injection With Gonadotrophins and Gonadotrophin-Releasing Hormone Analogues: Agonists and Antagonists,” Human Reproduction, vol. 14, Suppl. 1, 1999, pp. 207-221.
Felberbaum et al., “Preserved Pituitary Response Under Ovarian Stimulation with HMG and GnRH Antagonists (Cetrorelix) in Women with Tubal Infertility,”European Journal of Obstetrics&Gynecology and Reproductive Biology, vol. 61, 1995, pp. 151-155.
Felberbaum et al., “Ovarian Stimulation for Assisted Reproduction with HMG and Concomitant Midcycle Administration of the GnRH Antagonist Cetrorelix According to the Multiple Dose Protocol: A Prospective Uncontrolled Phase III Study,”Human Reproduction, vol. 15, No. 5, 2000, pp. 1015-1020.
Fraser et al., “Control of the Preovulatory Luteinizing Hormone Surge by Gonadotropin-Releasing Hormone Antagonists,”Trends Endocrinol Metal, vol. 5, No. 2, 1994, pp. 87-93.
Klingmüller et al., “Hormonal Responses to the New Potent GnRH Antagonist Cetrorelix,”Acta Endocrinologica, No. 128, 1993, pp. 15-18.
Ludwig et al., “Significant Reduction of the Incidence of Ovarian Hyperstimulation Syndrome (OHSS) by Using the LHRH Antagonist Cetrorelix (Cetrotide) in Contolled Ovarian Stimulation for Assisted Reproduction,”Arch Gynecol Obstet, No. 264, 2000, pp. 29-32.
Niwa et al., “Measurement of the Novel Decapeptide Cetrorelix in Human Plasma and Urine by Liquid Chromatography-Electrospray Ionization Mass Spectrometry,”Journal of Chromatography, vol. B, No. 729, 1999, pp. 245-253.
Olivennes et al., “The Single or Dual Administration of the Gonadotropin-Releasing Hormone Antagonist Cetrorelix in an In Vitro Fertilization-Embryo Transfer Program,”Fertility and Sterility, vol. 62, No. 3, 1994, pp. 468-476.
Olivennes et al., “GnRH Antagonist in Single-Dose Applications,”Human Reproduction Update, vol. 6, No. 4, 2000, pp. 313-317.
Oliveness et al., “Prospective, Randomized, Controlled Study of In Vitro Fertilization-Embry
Engel Jürgen
Reissmann Thomas
Sauerbier Dieter
Wichert Burkhard
Minnifield N. M.
Pillsbury & Winthrop LLP
Zentaris GmbH
LandOfFree
Preparation and use of oligopeptide lyophilisate for gonad... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation and use of oligopeptide lyophilisate for gonad..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation and use of oligopeptide lyophilisate for gonad... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435426